Chemed (CHE) Stock Price, News & Analysis

Company Overview

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Key Stats

• Today's Range: $447.68 to $455.43
• 50-Day Range: $412.98 to $558.68
• 52-Week Range: $408.42 to $623.60
• Volume: 174,873 shs
• Average Volume: 176,749 shs
• Market Capitalization: $6.57 billion
• P/E Ratio: 23.20
• Dividend Yield: 0.53%
• Price Target: $579.75
• Consensus Rating: Moderate Buy

Chemed Stock Analysis - MarketRank™

Chemed scored higher than 100% of companies evaluated by MarketBeat, and ranked 7th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Chemed has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Chemed has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.73%

Earnings Growth

Earnings for Chemed are expected to grow by 8.73% in the coming year, from $21.43 to $23.30 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chemed is 23.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chemed is 23.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.26.

Price to Earnings Growth Ratio

Chemed has a PEG Ratio of 2.51. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Chemed has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.69% of the float of Chemed has been sold short.

Short Interest Ratio / Days to Cover

Chemed has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemed has recently decreased by 1.03%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Chemed has a dividend yield of 0.53%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Chemed has been increasing its dividend for 16 years.

Dividend Coverage

The dividend payout ratio of Chemed is 12.34%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Chemed will have a dividend payout ratio of 10.30% next year. This indicates that Chemed will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.9 / 5
• Environmental Score: -0.33

Percentage of Shares Shorted

2.69% of the float of Chemed has been sold short.

Short Interest Ratio / Days to Cover

Chemed has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemed has recently decreased by 1.03%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.68

News Sentiment

Chemed has a news sentiment score of 1.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Chemed this week, compared to 11 articles on an average week.

Search Interest

Only 2 people have searched for CHE on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

MarketBeat Follows

3 people have added Chemed to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Chemed insiders have sold 4,963.73% more of their company's stock than they have bought. Specifically, they have bought $83,420.00 in company stock and sold $4,224,163.00 in company stock.

Percentage Held by Insiders

Only 3.29% of the stock of Chemed is held by insiders.

Percentage Held by Institutions

95.85% of the stock of Chemed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CHE Stock Analysis - Frequently Asked Questions

How have CHE shares performed this year?

Chemed's stock was trading at $529.80 at the beginning of 2025. Since then, CHE stock has decreased by 14.8% and is now trading at $451.2180.

How were Chemed's earnings last quarter?

Chemed Corporation (NYSE:CHE) released its quarterly earnings data on Tuesday, July, 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.02 by $1.75. The business's quarterly revenue was up 3.8% compared to the same quarter last year.
Read the conference call transcript.

Who are Chemed's major shareholders?

Chemed's top institutional investors include State Street Corp (3.27%), Geode Capital Management LLC (2.44%), William Blair Investment Management LLC (2.32%) and Impax Asset Management Group plc (1.84%). Insiders that own company stock include Kevin J Mcnamara, Spencer S Lee, David Patrick Williams, Andrea R Lindell, George J Walsh III, Patrick P Grace, Michael D Witzeman, Brian C Judkins and Nicholas Michael Westfall.
View institutional ownership trends.

How do I buy shares of Chemed?

Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Chemed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chemed investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Record date for 6/17 Dividend: 5/29/2025
• Ex-Dividend for 6/17 Dividend: 5/29/2025
• Dividend Payable: 6/17/2025
• Last Earnings: 7/29/2025
• Record date for 8/29 Dividend: 8/11/2025
• Ex-Dividend for 8/29 Dividend: 8/11/2025
• Today: 8/28/2025
• Dividend Payable: 8/29/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:CHE
• CIK: 19584
• Web: www.chemed.com
• Phone: (513) 762-6690
• Fax: 513-762-6590
• Employees: 15,695
• Year Founded: 1970

Price Target and Rating

• Average Price Target for Chemed: $579.75
• High Price Target: $650.00
• Low Price Target: $500.00
• Potential Upside/Downside: +28.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $19.45
• Trailing P/E Ratio: 23.20
• Forward P/E Ratio: 21.06
• P/E Growth: 2.51
• Net Income: $302 million
• Net Margins: 11.56%
• Pretax Margin: 15.44%
• Return on Equity: 25.83%
• Return on Assets: 17.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.86
• Quick Ratio: 1.83

Sales & Book Value

• Annual Sales: $2.43 billion
• Price / Sales: 2.70
• Cash Flow: $25.48 per share
• Price / Cash Flow: 17.71
• Book Value: $82.25 per share
• Price / Book: 5.49

Miscellaneous

• Outstanding Shares: 14,570,000
• Free Float: 14,093,000
• Market Cap: $6.57 billion
• Optionable: Optionable
• Beta: 0.46